In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background A safe, effective vaccine is essential to eradicating human immunodeficiency
virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/…

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% …

Sustainable Development Goal 2.2—to end malnutrition by 2030—includes the elimination
of child wasting, defined as a weight-for-length z-score that is more than two standard …

Mediation analysis in causal inference has traditionally focused on binary exposures and
deterministic interventions, and a decomposition of the average treatment effect in terms of …

Interventional effects for mediation analysis were proposed as a solution to the lack of
identifiability of natural (in)direct effects in the presence of a mediator-outcome confounder …

Child growth failure is associated with a higher risk of illness and mortality, 1 which contributed
to the United Nations Sustainable Development Goal 2.2 to end malnutrition by 2030. …